In this study, we have investigated the expression of the α and β chains of the IL-2 receptor (IL-2Rα, IL-2Rβ) both at the membrane and at transcrlptlonal levels during the lifespan of human embryonic fibroblasts. Here we show that the mAbs I0T14 and MIKβ1 directed against the IL-2 binding sites of the IL-2Rα and IL-2Rβ respectively, stain human embryonic fibroblasts early in their life span. Data from [125l]rIL2 cross-linking experiments show the simultaneous expression of two IL-2 binding peptldes of 70 and 55 kDa respectively on embryonic young fibroblasts as on lymphold activated cells. The p55 and the p70 IL-2 binding peptides are shown to be specific for the IL-2Rα and to the IL-2Rβ by the finding that these bands are abolished by excess amounts of cold IL-2 and mAbs directed against the IL-2 binding sites of the α and β chains. Scatchard analysis after [125I]IL-2 labelling shows the presence of both high affinity (150 sites with a Kd of 147 pM) and low affinity (1100 sites with a Kd of 4 nM) IL-2 binding sites. Northern blot and dot blot analysis show the presence of specific transcripts for the IL-2Rα and IL-2Rβ genes in early passaged fibroblasts. By contrast, In senescent cultures, only the IL-2Rβ transcript were detected. Finally, IL-2 at low concentrations (36 pM) down modulates the level of the intercellular adhesion molecule ICAM-1 in young but not in senescent cultures. Changes in the expression of the IL-2Rα during aging process probably affect the regulation of the ICAM-1 dependent flbroblastlc functions.
1 August 1988 in Biochemical and Biophysical Research Communications
DNA vaccination and all-trans retinoic acid (ATRA) result in a survival advantage in a mouse model of acute promyelocytic leukemia (APL). Depletion of CD4+ or CD8+ cells abolished this effect. CD4+ depletions of long-term survivors resulted in relapse and death within 3 months, thus demonstrating the need of both CD4+ and CD8+ subsets for the generation of DNA-driven antileukemic immune responses and underscoring a crucial role of CD4+ cells in the maintenance of durable remissions. Degranulation and cytotoxic carboxyfluorescein diacetate succinimidyl ester–based assays showed major histocompatibility complex–restricted APL-specific T cell–mediated immune responses. Sorted APL-specific CD8+CD107a+ T cells showed an increase of antileukemic activity. Effectors from ATRA + DNA–treated mice were shown to secrete interferon-γ when stimulated with either APL cells or peptides from the promyelocytic leukemia-RARα vaccine-derived sequences as detected by ELISpot assays. Our results demonstrate that DNA vaccination with ATRA confers the effective boosting of interferon-γ–producing and cytotoxic T cells in the leukemic mice.
During transformation, myelodysplastic syndromes (MDS) are characterized by reducing apoptosis of bone marrow (BM) precursors. Mouse models of high risk (HR)-MDS and acute myelogenous leukemia (AML) post-MDS using mutant NRAS and overexpression of human BCL-2, known to be poor prognostic indicators of the human diseases, were created. We have reported the efficacy of the BCL-2 inhibitor, ABT-737, on the AML post-MDS model; here, we report that this BCL-2 inhibitor also significantly extended survival of the HR-MDS mouse model, with reductions of BM blasts and lineage negative/Sca1+/KIT+ (LSK) cells. Secondary transplants showed increased survival in treated compared to untreated mice. Unlike the AML model, BCL-2 expression and RAS activity decreased following treatment and the RAS:BCL-2 complex remained in the plasma membrane. Exon-specific gene expression profiling (GEP) of HR-MDS mice showed 1952 differentially regulated genes upon treatment, including genes important for the regulation of stem cells, differentiation, proliferation, oxidative phosphorylation, mitochondrial function, and apoptosis; relevant in human disease. Spliceosome genes, found to be abnormal in MDS patients and downregulated in our HR-MDS model, such as Rsrc1 and Wbp4, were upregulated by the treatment, as were genes involved in epigenetic regulation, such as DNMT3A and B, upregulated upon disease progression and downregulated upon treatment.
About Me
UMR-S 1131, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 PARIS, FRANCE
UMR-S 1131, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 PARIS, FRANCE